JP6363120B2 - ベンゾオキサゼピン化合物の作製方法 - Google Patents

ベンゾオキサゼピン化合物の作製方法 Download PDF

Info

Publication number
JP6363120B2
JP6363120B2 JP2015562108A JP2015562108A JP6363120B2 JP 6363120 B2 JP6363120 B2 JP 6363120B2 JP 2015562108 A JP2015562108 A JP 2015562108A JP 2015562108 A JP2015562108 A JP 2015562108A JP 6363120 B2 JP6363120 B2 JP 6363120B2
Authority
JP
Japan
Prior art keywords
bromo
reacting
acid
prepared
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015562108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512209A (ja
Inventor
レミ アンゲラウド，
レミ アンゲラウド，
ダニエル アール． ボードリ，
ダニエル アール． ボードリ，
ダイアン イー． カルレラ，
ダイアン イー． カルレラ，
シャント マルホトラ，
シャント マルホトラ，
トラヴィス レマーチュク，
トラヴィス レマーチュク，
フレデリク エスティー−ジーン，
フレデリク エスティー−ジーン，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2016512209A publication Critical patent/JP2016512209A/ja
Application granted granted Critical
Publication of JP6363120B2 publication Critical patent/JP6363120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015562108A 2013-03-13 2014-03-12 ベンゾオキサゼピン化合物の作製方法 Active JP6363120B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017135083A Division JP6442005B2 (ja) 2013-03-13 2017-07-10 ベンゾオキサゼピン化合物の作製方法
JP2018044050A Division JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法

Publications (2)

Publication Number Publication Date
JP2016512209A JP2016512209A (ja) 2016-04-25
JP6363120B2 true JP6363120B2 (ja) 2018-07-25

Family

ID=50241450

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015562108A Active JP6363120B2 (ja) 2013-03-13 2014-03-12 ベンゾオキサゼピン化合物の作製方法
JP2017135083A Active JP6442005B2 (ja) 2013-03-13 2017-07-10 ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja) 2013-03-13 2018-08-16 ベンゾオキサゼピン化合物の作製方法
JP2018219226A Pending JP2019089762A (ja) 2013-03-13 2018-11-22 ベンゾオキサゼピン化合物の作製方法
JP2020032846A Pending JP2020114814A (ja) 2013-03-13 2020-02-28 ベンゾオキサゼピン化合物の作製方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017135083A Active JP6442005B2 (ja) 2013-03-13 2017-07-10 ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja) 2013-03-13 2018-03-12 ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja) 2013-03-13 2018-08-16 ベンゾオキサゼピン化合物の作製方法
JP2018219226A Pending JP2019089762A (ja) 2013-03-13 2018-11-22 ベンゾオキサゼピン化合物の作製方法
JP2020032846A Pending JP2020114814A (ja) 2013-03-13 2020-02-28 ベンゾオキサゼピン化合物の作製方法

Country Status (15)

Country Link
US (1) US9303043B2 (OSRAM)
EP (3) EP3404032B1 (OSRAM)
JP (6) JP6363120B2 (OSRAM)
KR (3) KR101821468B1 (OSRAM)
CN (2) CN105377856B (OSRAM)
AR (1) AR095365A1 (OSRAM)
AU (3) AU2014230812B2 (OSRAM)
BR (1) BR112015020716A2 (OSRAM)
CA (6) CA3005103A1 (OSRAM)
IL (1) IL240793A0 (OSRAM)
MX (1) MX2015011438A (OSRAM)
NZ (1) NZ711192A (OSRAM)
RU (2) RU2649976C2 (OSRAM)
SG (2) SG11201507394RA (OSRAM)
WO (1) WO2014140073A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
CN114716377A (zh) * 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
JP4677100B2 (ja) * 1998-10-23 2011-04-27 ダウ・アグロサイエンス・エル・エル・シー ３−（置換フェニル）−５−（置換シクロプロピル）−１，２，４−トリアゾール化合物
HUP0400164A2 (hu) 2001-07-12 2004-07-28 Avecia Ltd. Mikrokapszulázott katalizátor, eljárás előállítására és alkalmazása
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
NZ575336A (en) * 2006-10-23 2012-04-27 Sgx Pharmaceuticals Inc Bicyclic triazoles as protein kinase modulators
ES2531002T3 (es) * 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
TWI443102B (zh) 2008-03-31 2014-07-01 Genentech Inc 苯并哌喃及苯并氧呯ｐｉ３ｋ抑制劑化合物及其使用方法
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
NZ599090A (en) * 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k
US9409918B2 (en) * 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
CA2825966A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
NO3175985T3 (OSRAM) * 2011-07-01 2018-04-28
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Also Published As

Publication number Publication date
CA2897618A1 (en) 2014-09-18
AU2014230812B2 (en) 2016-04-07
JP2016512209A (ja) 2016-04-25
EP3404032B1 (en) 2025-07-02
MX2015011438A (es) 2016-02-03
CN108929333A (zh) 2018-12-04
RU2649976C2 (ru) 2018-04-06
EP3404032A3 (en) 2019-03-13
JP2019089762A (ja) 2019-06-13
KR20170070270A (ko) 2017-06-21
JP2019031493A (ja) 2019-02-28
RU2015138488A (ru) 2017-04-20
CA3005112A1 (en) 2014-09-18
CA2948763C (en) 2018-04-24
US20140275523A1 (en) 2014-09-18
HK1215433A1 (zh) 2016-08-26
EP3404032C0 (en) 2025-07-02
CA3005103A1 (en) 2014-09-18
NZ711192A (en) 2019-04-26
KR20180070715A (ko) 2018-06-26
WO2014140073A1 (en) 2014-09-18
EP3404032A2 (en) 2018-11-21
US9303043B2 (en) 2016-04-05
CA2948765A1 (en) 2014-09-18
JP2018150298A (ja) 2018-09-27
JP2018008959A (ja) 2018-01-18
KR20150119033A (ko) 2015-10-23
AU2016204432B2 (en) 2017-12-07
CA2948763A1 (en) 2014-09-18
RU2018109979A (ru) 2019-02-28
EP2970329A1 (en) 2016-01-20
CN105377856B (zh) 2018-05-22
AU2014230812A1 (en) 2015-09-03
JP6442005B2 (ja) 2018-12-19
CN105377856A (zh) 2016-03-02
KR101871133B1 (ko) 2018-06-25
KR101821468B1 (ko) 2018-01-23
JP2020114814A (ja) 2020-07-30
EP3845540A1 (en) 2021-07-07
AU2018201393A1 (en) 2018-03-15
AU2014230812A8 (en) 2015-09-10
SG10201706760YA (en) 2017-10-30
CA3005118A1 (en) 2014-09-18
SG11201507394RA (en) 2015-10-29
IL240793A0 (en) 2015-10-29
AR095365A1 (es) 2015-10-14
JP6663459B2 (ja) 2020-03-11
BR112015020716A2 (pt) 2017-07-18
AU2016204432A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
JP6442005B2 (ja) ベンゾオキサゼピン化合物の作製方法
CN104718212B (zh) 制备噻吩并嘧啶化合物的方法
EP3359527A1 (en) Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
AU2022240688A1 (en) Furan fused ring-substituted glutarimide compound
EP4066895A1 (en) Compound having lysophosphatidic acid receptor agonistic activity and pharmaceutical use of said compound
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
WO2025247067A1 (zh) Kif18A抑制剂
HK1244272B (zh) 制备噻吩并嘧啶化合物的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180627

R150 Certificate of patent or registration of utility model

Ref document number: 6363120

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250